Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Chimerix Inc 2505 MERIDIAN PARKWAY SUITE 100 DURHAM NC 27713 USA

www.chimerix.com Employees: 81 P: 919-806-1074 F: 919-806-1146

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Chimerix is a biopharmaceutical company which develop medicines for lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program ONC201, is in development for H3 K27M-mutant glioma. Chimerix is based in DURHAM, N.C.

Key Statistics

Overview:

Market Capitalization, $K 801,086
Enterprise Value, $K 770,036
Shares Outstanding, K 93,804
Float, K 81,516
% Float 86.90%
Short Volume Ratio 0.27
% of Insider Shareholders 13.10%
% of Institutional Shareholders 45.42%

Financials:

Annual Sales, $ 210 K
Annual Net Income, $ -88,390 K
Last Quarter Sales, $ 60 K
Last Quarter Net Income, $ -22,950 K
EBIT, $ -96,560 K
EBITDA, $ -99,940 K

Growth:

1-Year Return 844.69%
3-Year Return 75.00%
5-Year Return 493.06%
5-Year Revenue Growth -98.32%
5-Year Earnings Growth -15.12%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 03/21/25
Next Earnings Date 05/07/25
Earnings Per Share ttm -0.99
EPS Growth vs. Prev Qtr 3.85%
EPS Growth vs. Prev Year -25.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CMRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -60.22%
Return-on-Assets % -52.21%
Profit Margin % -42,090.48%
Debt/Equity 0.00
Price/Sales 3,783.13
Price/Cash Flow N/A
Price/Book 6.32
Book Value/Share 1.35
Interest Coverage -2.98
60-Month Beta -0.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar